EUCRW (Eucrates Biomedical Acquisition) Net Margin %: 0.00% (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EUCRW Eucrates Biomedical Acquisition Corp EUCRW
22 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Eucrates Biomedical Acquisition Net Margin %?

Eucrates Biomedical Acquisition EUCRW 22 Net Margin % is 0.00% as of Dec. 2022. GuruFocus rates EUCRW with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Net margin is calculated as Net Income divided by its Revenue. Eucrates Biomedical Acquisition's Net Income for the three months ended in Dec. 2022 was $0.14 Mil. Eucrates Biomedical Acquisition's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Eucrates Biomedical Acquisition's net margin for the quarter that ended in Dec. 2022 was 0.00%.

The historical rank and industry rank for Eucrates Biomedical Acquisition's Net Margin % or its related term are showing as below:


EUCRW's Net Margin % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 7.35
* Ranked among companies with meaningful Net Margin % only.

Eucrates Biomedical Acquisition  (NAS:EUCRW) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Eucrates Biomedical Acquisition Net Margin % Related Terms

Eucrates Biomedical Acquisition Net Margin % Historical Data

* Premium members only.

The historical data trend for Eucrates Biomedical Acquisition's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eucrates Biomedical Acquisition Net Margin % Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Net Margin %
0.00 0.00 0.00

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EUCRW vs FXCO, AEHA, LMAO: Net Margin % Comparison

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition Net Margin % vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Net Margin % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Net Margin % falls into.


EUCRW
22GF Score
Eucrates Biomedical Acquisition Corp EUCRW
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eucrates Biomedical Acquisition Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Eucrates Biomedical Acquisition's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=2.42/0
= %

Eucrates Biomedical Acquisition's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin=Net Income (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=0.142/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Eucrates Biomedical Acquisition (EUCRW) has a Net Margin % of 0.00% as of Dec. 2022. Net margin is the ratio of total net income to net sales. View historical data on Eucrates Biomedical Acquisition and its competitors.
Is Eucrates Biomedical Acquisition's Net Margin % too high?
Eucrates Biomedical Acquisition's current Net Margin % is 0.00%. Overall, Eucrates Biomedical Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Eucrates Biomedical Acquisition's Net Margin % compare to FXCO and AEHA?
Eucrates Biomedical Acquisition's Net Margin % of 0.00% can be compared against companies in the Diversified Financial Services industry. The industry median Net Margin % is 7.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Diversified Financial Services company?
The median Net Margin % among Diversified Financial Services companies is 7.35, based on 102 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eucrates Biomedical Acquisition and its competitors. For the Diversified Financial Services industry, the median Net Margin % is 7.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eucrates Biomedical Acquisition's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eucrates Biomedical Acquisition stock overvalued right now?
Eucrates Biomedical Acquisition (EUCRW) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Eucrates Biomedical Acquisition's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eucrates Biomedical Acquisition (EUCRW), the current Net Margin % is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eucrates Biomedical Acquisition Business Description

Address 250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Eucrates Biomedical Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EUCRW

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price